INTRODUCTION
============

Osteoarthritis (OA), the most common form of arthritis, is a leading cause of disability and has a great impact on public health \[[@b1-kjim-2017-304]\]. With the aging of the population and rising rates of obesity, the prevalence of knee OA is increasing \[[@b2-kjim-2017-304]\]. Roughly 25% of adults aged 55 years or older have knee pain on most days, and most of these people have OA \[[@b3-kjim-2017-304]\]. In Korea, the prevalence of radiologic OA and symptomatic OA was reported as 37.3% and 24.2%, respectively, in an elderly community residents' survey \[[@b4-kjim-2017-304]\]. In a recent report using the Fifth Korean National Health and Nutrition Examination Survey (2010 to 2012), the number of knee OA patients with symptoms and radiological findings in males and females was 4.5% and 19%, respectively \[[@b5-kjim-2017-304]\].

To date, there is no known cure for OA, and management of knee OA patients remains palliative treatment. Several therapies are available to reduce OA-associated symptoms. The most commonly used treatment options are focused on pain relief and improvement of joint function, which include nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics (acetaminophen or opioids), and symptomatic slow acting drugs for osteoarthritis (SYSADOA). These drugs are recommended in many knee OA guidelines \[[@b6-kjim-2017-304]-[@b10-kjim-2017-304]\]. In addition, corticosteroid (CS) intra-articular injection (IAI) can be a treatment option for knee OA. However, consensus on therapeutic strategies is inadequate and guidance on first-line therapies or drug combination is poorly implemented. This leads to great variability in the use of different drugs for knee OA in clinical practice. In clinical practice, physicians usually choose a treatment for knee OA by considering the treatment's effects and adverse events depending on the patient's condition irrespective of health care costs and patient safety \[[@b11-kjim-2017-304]\].

This study aimed to evaluate the treatment patterns of knee OA patients in South Korea.

METHODS
=======

Data source and study population
--------------------------------

### Korean Health Insurance Review and Assessment Service database

South Korea has a universal health coverage system in which the National Health Insurance program covers almost 100% of the Korean population, approximately 50 million people. Korean Health Insurance Review and Assessment Service (HIRA) database contains individual beneficiary information, in addition to healthcare service information such as diagnosis, procedures, prescriptions, and the type of institution or department \[[@b12-kjim-2017-304]\].

### Study population

On the basis of our previous validation study \[[@b13-kjim-2017-304]\], knee OA patients were identified by using the knee OA diagnostic code (M17) or any OA diagnostic code (M15 to M19) in combination with a procedure for a knee X-ray in the same claim. After excluding patients with inflammatory arthritis such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis, we constructed a database of patients ≥ 40 years of age with knee OA ([Fig. 1](#f1-kjim-2017-304){ref-type="fig"}). To evaluate healthcare usage rates of knee OA patients, the type of institution and department frequently visited during the follow-up period was analyzed. For all knee OA patients in 2014, the number of comorbidities and the Charlson comorbidity index (CCI) was tabulated.

Treatment patterns of knee OA
-----------------------------

### Oral medications for knee OA patients

Medications used in our study included oral NSAIDs, analgesics such as acetaminophen, tramadol, and their combination. Well-known SYSADOAs such as diacerein, avocado soybean unsaponifiables (ASU), and chondroitin were included in this study, but glucosamine was excluded since it was reimbursed by HIRA only since 2011. Instead, herbal drugs combining herbal extracts such as herbal SYSADOA A \[[@b14-kjim-2017-304]\] (a mixed extract of three herbs, *Clematis mandshurica, Prunella vulgaris, and Trichosanthes kirilowii*), herbal SYSADOA B \[[@b15-kjim-2017-304],[@b16-kjim-2017-304]\] (an ethanol extract prepared from 12 plant sources, *Chaenomelis fructus, Achyranthis radix, Acanthopanax cortex, Cinnamomi cortex, Gentianae macrophyllae radix, Clematidis radix, Angelica gigantis radix, Cnidii rhizoma, Gastrodiae rhizoma, Carthami flos, Saposhnikoviae radix,* and *Dipsaci radix*), and herbal SYSADOA C \[[@b17-kjim-2017-304]\] (a purified extract from a mixture of six oriental herbs, *Ledebouriellae radix, Achyranthis radix, Acanthopanacis cortex, Cibotii rhizoma, Glycine semen,* and *Eucommiae cortex*). In addition, the use of oral CS was also investigated.

### Utilization of oral medications

Drug utilization was described in terms of prevalence of use, which was defined by the number of doses at any time during follow-up. Quantitative use of each different medication was described using medication possession ratios (MPRs). The MPR is a standard measurement that is defined as the number of days for which medication is available divided by the number of days of treatment (time from first to last prescription) \[[@b15-kjim-2017-304]\]. Regular use of a specific medication was defined as a MPR of 50%, and occasional use of a specific medication was defined as a MPR of 25%. The number and the types of drugs used during the follow-up period were estimated.

### Utilization rates of corticosteroid intra-articular injection

For evaluating the utilization rates of CS IAI, we counted claims with a knee OA diagnostic code that also included the procedure code of CS IAI within the same claim. The frequency of CS IAI was also evaluated according to age and gender.

Statistical analysis
--------------------

Baseline characteristics of the study population were presented by demographics, medical care utilization (including type of institution or department), and comorbidities that were most frequently observed during the follow-up period. We used descriptive analysis to examine the drug utilization in knee OA patients. Drugs were categorized into four categories: NSAIDs, analgesics, SYSADOAs, and CS. The usage frequency of each drug and combinations of each category of drugs were calculated. *p* values less than 0.05 were considered statistically significant. All of the analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA).

Ethics statement
----------------

The Institutional Review Board (IRB) of Hanyang University determined that this study was exempt from IRB review because we used existing data and the information could not be linked to individual subjects (HYUH-2016-06-008-002). Informed consent was not required because data was de-identified and collected retrospectively.

RESULTS
=======

Baseline characteristics
------------------------

We identified 2,016,516 knee OA patients from 2014. Their mean age ± standard deviation was 63.2 ± 10.8 years and 71.5% were female ([Table 1](#t1-kjim-2017-304){ref-type="table"}). Most of the patients went to a private clinic (n = 1,310,406, 65%) or a community hospital (n = 354.391, 17.6%). More than half of the patients (72.6%) visited an orthopedic surgery department. Nearly half of the patients had at least two comorbidities (n = 972,546, 48.2%). The most frequent comorbidity was chronic pulmonary disease (n = 692,582, 34.3%), followed by peptic ulcer disease (n = 656,114, 32.5%) and mild liver disease (n = 492,225, 24.4%). The mean CCI score was 2.56 ± 1.78.

Patterns of oral medications in knee OA patients
------------------------------------------------

### The prevalence of oral medications for knee OA patients

Among the total patients, 12.0% of patients did not use any medications for 1 year. The medication used most frequently at any time during follow-up was NSAIDs (82.5%), followed by SYSADOA (43.4%) and analgesics (32.2%). Among SYSADOAs, diacerein (16.6%) and herbal SYSADOA A (16.1%) were the most commonly used, followed by ASU (8.2%) and herbal SYSADOA B (7.9%). The percentage of total herbal SYSADOAs were high as 29.7%. Among patients who used analgesics, tramadol/acetaminophen combination product was the most frequently used (29.4%), while single use of acetaminophen was only 3.7%. Oral CS was used in 8.6% of patients ([Table 2](#t2-kjim-2017-304){ref-type="table"}).

Quantitative drug utilization was estimated by taking the percentages of patients defined as occasional use (MPR ≥ 25%) and regular use (MPR ≥ 50%) for each drug. The data is presented in [Table 2](#t2-kjim-2017-304){ref-type="table"}. In this quantitative drug utilization, percentage of drug use was decreased along the MPRs for occasional use and regular use. When we analyzed a group of regular users, the use of NSAIDs was substantially decreased from 82.5% to 48.8%, while the use of SYSADOAs (37.3%) and analgesics (23.7%) was not significantly different. The regular use (MPR ≥ 50%) of oral CS was also relatively high at 6.7% ([Table 2](#t2-kjim-2017-304){ref-type="table"}).

The number of drugs patients experienced during follow-up
---------------------------------------------------------

More than half of knee OA patients were treated with drugs from at least two categories within a calendar year: 37.2% of patients were treated with drugs from two categories and 16.6% were treated with drugs from three categories. NSAIDs alone were the most common treatment pattern (27.2%), although analgesics alone or SYSADOAs alone were also observed. Among patients treated with multiple drugs, NSAIDs in combination with SYSADOAs (22.3%), or a combination of NSAIDs, SYSADOAs, and analgesics (13.0%) were commonly observed. We also observed patients that were treated with drug combinations that did not include SYSADOAs: NSAIDs in combination with analgesics (11.9%), NSAIDs in combination with CS (1.9%), and a combination of NSAIDs, analgesics and CS (1.7%) ([Table 3](#t3-kjim-2017-304){ref-type="table"}).

Intra-articular injection of CS in knee OA patients
---------------------------------------------------

A total of 3,567 patients (0.18%) received CS IAI at least once in 2014. Patients who received CS IAI were slightly older than patients who did not receive IAI (64.4 ± 10.9 vs. 63.2 ± 10.8, *p* \< 0.01). Females more frequently received CS IAI (75.7% vs. 71.5%, *p* \< 0.01) ([Supplementary Fig. 1A](#SD1){ref-type="supplementary-material"}). However, the frequency of females was higher than males in patients that received only one or two times of IAI with CS while the frequency of males was higher in groups receiving over three times the number of IAIs with CS ([Supplementary Fig. 1B](#SD1){ref-type="supplementary-material"}). Comorbidities (CCI score, 3.1 ± 2.1 vs. 2.6 ± 1.8, *p* \< 0.01) and the use of multiple drug combinations (three types of drugs, 23.4% vs. 14.9%, *p* \< 0.01) were greater in patients with CS IAI. In a multivariable logistic model adjusted by type of institution, type of department, female (odds ratio \[OR\], 1.3; 95% confidence interval \[CI\], 1.2 to 1.4) and the number of comorbidities (OR, 1.5; 95% CI, 1.3 to 1.6 in patients with one comorbidity; OR, 2.1; 95% CI, 1.9 to 2.4 in patients with more than two comorbidities) were associated with IAI with CS in patients with knee OA ([Table 4](#t4-kjim-2017-304){ref-type="table"}).

DISCUSSION
==========

In this study, we extracted a large dataset of knee OA patients (n = 2,016,516) using a nation-wide Korean claims database and identified patterns of medication use for knee OA patients. Most of the patients (82.5%) were treated with oral NSAIDs and nearly half of the patients (48.8%) used NSAIDs regularly. The use of SYSADOAs, particularly herbal SYSADOAs, was commonly observed and SYSDOAs were frequently used in combination with NSAIDS. Unexpectedly, the use of oral CS was high in knee OA patients. On the other hand, CS IAI was not common. Female patients, older age, and the number of comorbidities were associated with CS IAI in knee OA patients.

We identified some unique features of medication use specific to Korean patients with knee OA that differed from medication use in other countries. First, the prevalence of NSAID use (82.5%) in Korean patients was much higher than the 26.0% to 58.1% recently reported from the USA using osteoarthritis initiative (OAI) data \[[@b18-kjim-2017-304]\]. Regular use of NSAIDs (48.8%) was also much higher than the 14.4% of patients reported in Spain \[[@b11-kjim-2017-304]\]. This pattern may be related to our data source, which was a claims database consisting of prescriptions from physicians. For instance, knee OA patients with mild symptoms can use over-the-counter drug by themselves, whereas patients with severe symptoms are treated with NSAIDs by physicians. Many patients treated with NSAIDs in our study were also treated with other drugs such as SYSADOAs, analgesics, or CS and this pattern reflected their uncontrolled symptoms. In Korea, patients more commonly used analgesics, such as acetaminophen or paracetamol, rather than NSAIDs as over the counter drugs for pain control \[[@b19-kjim-2017-304]\]. Hence physicians tend to prescribe NSAIDs frequently rather than acetaminophen.

Second, the prevalence of SYSADOA use (43.4%) was comparable to other countries. 27.5% to 54.0% in OAI \[[@b18-kjim-2017-304]\] and its regular use (37.3%) was 46.6% in a study from Spain \[[@b11-kjim-2017-304]\]. However, the individual drug selection was different from other countries. In the United States and European countries, glucosamine or chondroitin was frequently used, while new herbal medications were frequently prescribed in Korea. Until recently, glucosamine and chondroitin were widely used in Korea for the general population and not limited to knee OA patients \[[@b20-kjim-2017-304]\], even though it was covered by medical reimbursement. However, these compounds were excluded from Korean reimbursement guidelines based on the the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) \[[@b21-kjim-2017-304]\] and their use has since dramatically decreased. A recent clinical trial suggested that a combined chondroitin sulfate/glucosamine treatment for painful knee OA was effective \[[@b22-kjim-2017-304]\]; however, another meta-analysis reported that there was no evidence to support the use of glucosamine for knee OA \[[@b23-kjim-2017-304]\]. Because of the controversy surrounding the effectiveness of glucosamine for knee OA patients, reimbursement has become difficult.

Finally, the use of oral CS was high in Korean patients with knee OA. Many factors contribute to the inflammatory process in OA, which include the synthesis and release of inflammatory cytokines into the joint environment by multiple tissues. Thus, CS can be a potent anti-inflammatory agent in OA treatments, although the effectiveness and safety of CS treatments are unclear \[[@b24-kjim-2017-304]\]. Treatment guidelines typically recommend CS IAI, but not oral CS, for knee OA patients \[[@b9-kjim-2017-304]\].

The extremely high use of oral CS in Korean knee OA patients can be explained by several factors. For example, patients with comorbidities such as COPD and asthma could have been managed with CS. NSAIDs could have been ineffective in some patients, or the patients had a contraindication for NSAIDs, and thus may have had CS prescribed. Also, some patients who had undifferentiated arthritis or inflammatory arthritis patients not satisfied RA, AS, or psoriatic arthritis criteria could have received an OA diagnostic code. Nevertheless, since the prevalence of CS use in knee OA patients was extremely high in this study, further studies are needed to investigate the possibility of CS abuse in this population.

There is controversy surrounding the use of CS IAI. A recent review \[[@b8-kjim-2017-304]\] suggested that CS IAI may be associated with a moderate improvement in pain and a small improvement in physical function, although the quality of the evidence was poor. The 2013 guidelines from the American Academy of Orthopedic Surgeons did not provide any recommendations supporting or discouraging the use of CS IAI because the evidence was inconclusive \[[@b6-kjim-2017-304]\]. On the other hand, the 2012 guidelines from the American College of Rheumatology conditionally recommended CS IAI for knee OA \[[@b7-kjim-2017-304]\], Furthermore, both the 2014 National Institute for Health and Care Excellence guidelines \[[@b8-kjim-2017-304]\] and the 2014 Osteoarthritis Research Society International (OARSI) guidelines \[[@b9-kjim-2017-304]\] stated that CS IAI was appropriate for knee OA. In clinical practice, CS IAI is widely considered the most acutely effective nonsurgical treatment for OA and typically provides substantial pain relief. However, the effect was short-term which was corroborated in all meta-analyses \[[@b8-kjim-2017-304]\]. Some patients with knee OA do not respond to CS IAI, perhaps because they do not have a substantial inflammatory component to their OA pain. In our study, the prevalence of CS IAI use was not high (0.18%), but the patients who received CS IAI were older and had higher numbers of comorbidities. This observation indicate that CS IAI is possibly prescribed for patients who do not tolerate or adhere to oral medicines. Also, there may not be other treatment options for these patients, because they do not tolerate knee replacement operations.

This study has several strengths. First, the large population size reduced selection bias and may be generalizable due to data drawn from a large nation-wide claims database. Second, this is the first study to present the utilization of a new herbal SYSADOA, which has been commonly prescribed in Korea. Third, quantifying the use of each different type of medication using MPR gave us the prevalence of regular users in knee OA patients, although this was a cross-sectional study design.

There are some limitations to this study. First, we could not estimate the usage of glucosamine which was not reimbursed as medicine, but as a health supplement. However, we included all drugs that were available in the clinic, which provided exact drug utilization at the national level. Second, there is a possibility that we did not include knee OA patients with mild symptoms. However, the total number of patients (n = 2,016,516) in our study was about 10% of the Korean population 40 years or older. The number of knee OA patients reported here was similar to the prevalence of knee OA previously reported. Therefore, our study population represented the total sub-population of knee OA patients in Korea. Third, the prevalence of intra-articular hyaluronic acid (HA) treatment was not assessed because of the variability of its patterns of use. The provision of an operational definition for this treatment in the claims database, and long-term study will provide information on the exact prevalence and sparing effect of NSAIDs and CS.

From this study, we have identified areas for future study. First, the long term safety related to NSAIDs use by knee OA patients should be evaluated, since NSAIDSs are typically used in the elderly who are also treated with other medications to manage associated comorbidities. Second, a review of the effectiveness of the continuous use of SYSADOAs is needed. Specifically, more evidence is needed to evaluate the effectiveness and safety of the new herbal medications because of lack of good evidences even though their high prevalence. Also, the safety of IAI with not only CS but also HA and their effects on decrease in the use of NSAIDs or analgesics is also an important research issue.

In Korea, the usage of SYSADOA or CS in knee OA patients was relatively high. Further studies on the effectiveness and safety of these treatment options for knee OA are needed.

KEY MESSAGE
===========

1\. The number of patients with at least one use of nonsteroidal anti-inf lammatory drugs (NSAIDs), analgesics, corticosteroid (CS), and symptomatic slow acting drugs for osteoarthritis (SYSADOA) were 82.5%, 32.2%, 8.6%, and 43.4%, respectively. For regular users, the use of NSAIDs was substantially decreased (48.8%), while the use of SYSADOA (37.3%) and CS (6.7%) were not significantly changed.

2\. In Korea, the use of SYSADOA or corticosteroids in knee osteoarthritis (OA) patients was relatively high and the new herbal SYSADOAs were frequently prescribed.

3\. The number of CS intra-articular injection users among knee OA patients was 0.18%; they were slightly older and more skewed towards females.
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###### 

Intra-articular injection with corticosteroids in knee osteoarthritis (OA) patients. (A) The usage of corticosteroid (CS) intra-articular injection (IAI) in knee OA patients. (B) The usage of CS IAI in knee OA patients per calendar year.

![Patient selection flow. OA, osteoarthritis.](kjim-2017-304f1){#f1-kjim-2017-304}

###### 

Baseline characteristics of patients with knee osteoarthritis

  Characteristic                                                       Value
  -------------------------------------------------------------------- ------------------
  Age                                                                  63.2 ± 10.8
  Female sex                                                           1,442,510 (71.5)
  Type of institution^[a](#tfn1-kjim-2017-304){ref-type="table-fn"}^   
   Tertiary hospital                                                   53,574 (2.7)
   General hospital                                                    171,826 (8.5)
   Community hospital                                                  354,391 (17.6)
   Clinic                                                              1,310,406 (65.0)
   Others                                                              126,319 (6.3)
  Type of department^[a](#tfn1-kjim-2017-304){ref-type="table-fn"}^    
   Internal Medicine                                                   138,183 (6.9)
   Orthopedic Surgery                                                  1,464,264 (72.6)
   Rehabilitation                                                      38,295 (1.9)
   Others                                                              375,774 (18.6)
  No. of comorbidities                                                 
   1                                                                   546,605 (27.1)
   ≥ 2                                                                 972,546 (48.2)
  Myocardial infarction                                                21,943 (1.1)
  Congestive heart failure                                             113,620 (5.6)
  Peripheral vascular disease                                          364,022 (18.1)
  Cerebrovascular disease                                              243,677 (12.1)
  Dementia                                                             117,794 (5.8)
  Chronic pulmonary disease                                            692,582 (34.3)
  Peptic ulcer disease                                                 656,114 (32.5)
  Mild liver disease                                                   492,255 (24.4)
  Diabetes without chronic complication                                485,567 (24.1)
  Diabetes with chronic complication                                   172,641 (8.6)
  Hemiplegia or paraplegia                                             20,932 (1.0)
  Renal disease                                                        34,275 (1.7)
  Any malignancy                                                       112,417 (5.6)
  Moderate or severe liver disease                                     8,244 (0.4)
  Metastatic solid tumor                                               9,175 (0.5)
  Charlson comorbidity index score                                     2.6 ± 1.8

Values are presented as mean ± SD or number (%).

Type of institution and type of department frequently visited during the follow-up period.

###### 

Medication utilization in patients with knee osteoarthritis

  Characteristic                     Any use^[a](#tfn2-kjim-2017-304){ref-type="table-fn"}^   Occasional use^[b](#tfn3-kjim-2017-304){ref-type="table-fn"}^   Regular use^[c](#tfn4-kjim-2017-304){ref-type="table-fn"}^
  ---------------------------------- -------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------
  NSAIDs                             1,664,518 (82.5)                                         1,221,533 (60.6)                                                983,783 (48.8)
   Nonselective NSAIDs               1,429,388 (70.9)                                         1,127,672 (55.9)                                                896,697 (44.5)
   Cox-2 inhibitor                   80,853 (4.0)                                             77,107 (3.8)                                                    70,578 (3.5)
  SYSADOA                            875,854 (43.4)                                           821,013 (40.7)                                                  751,391 (37.3)
   Diacerein                         334,761 (16.6)                                           297,476 (14.8)                                                  258,255 (12.8)
   Avocado soybean unsaponifiables   165,010 (8.2)                                            157,014 (7.8)                                                   143,913 (7.1)
   Chondroitin                       45,307 (2.3)                                             41,665 (2.1)                                                    37,426 (1.9)
   Herbal SYSADOA B                  158,577 (7.9)                                            147,145 (7.3)                                                   132,654 (6.6)
   Herbal SYSADOA A                  324,677 (16.1)                                           299,697 (14.9)                                                  268,620 (13.3)
   Herbal SYSADOA C                  114,258 (5.7)                                            108,519 (5.4)                                                   99,801 (5.0)
  Analgesics                         648,611 (32.2)                                           559,316 (27.7)                                                  478,199 (23.7)
   Acetaminophen                     75,423 (3.7)                                             63,553 (3.2)                                                    57,307 (2.8)
   Tramadol                          20,212 (1.0)                                             19,162 (1.0)                                                    17,622 (0.9)
   Acetaminophen + Tramadol          593,581 (29.4)                                           505,292 (25.1)                                                  424,539 (21.1)
  Corticosteroid                     173,591 (8.6)                                            150,419 (7.5)                                                   134,294 (6.7)

Values are presented as number (%).

NSAID, nonsteroidal anti-inflammatory drug; Cox-2, cyclooxygenase 2; SYSADOA, symptomatic slow-acting drug in osteoarthritis.

Any use was defined as any number of doses at any time during follow-up.

Occasional use was defined as a medication possession ratio (MPR) of 25%.

Regular use was defined as a MPR of 50%.

###### 

Number of drugs patients experienced by knee osteoarthritis patients during follow-up

  Type of drug                             No. (%)
  ---------------------------------------- ----------------
  Single drug                              632,856 (31.4)
   NSAIDs                                  549,292 (27.2)
   SYSADOA                                 47,190 (2.3)
   Analgesics                              33,111 (1.6)
   Corticosteroid                          3,263 (0.2)
  Two drugs                                749,655 (37.2)
   NSAIDs + SYSADOA                        448,932 (22.3)
   NSAIDs + Analgesics                     239,089 (11.9)
   NSAIDs + Corticosteroid                 37,275 (1.9)
   SYSADOA + Analgesics                    20,713 (1.0)
   SYSADOA + Corticosteroid                1,276 (0.1)
   Analgesics + Corticosteroid             2,370 (0.1)
  Three drugs                              334,420 (16.6)
   NSAIDs + SYSADOA + Analgesics           261,800 (13.0)
   NSAIDs + SYSADOA + Corticosteroid       37,879 (1.9)
   SYSADOA + Analgesics + Corticosteroid   1,277 (0.1)
   NSAIDs + Analgesics + Corticosteroid    33,464 (1.7)
  Other combinations                       56,787 (2.8)

NSAID, nonsteroidal anti-inf lammatory drug; SYSADOA, symptomatic slow-acting drug in osteoarthritis.

###### 

Factors associated with risk of intra-articular steroid injection in patients with knee osteoarthritis^[a](#tfn5-kjim-2017-304){ref-type="table-fn"}^

  Variable             Crude               Adjusted                       
  -------------------- ------------------- ---------- ------------------- ---------
  Age, yr              1.01 (1.01--1.01)   \< 0.01    1.00 (1.00--1.01)   0.04
   40--49 (ref)                                                           
   50--59              1.36 (1.19--1.55)   0.05                           
   60--69              1.28 (1.12--1.46)   0.99                           
   ≥ 70                1.55 (1.36--1.76)   \< 0.01                        
  Female sex           1.24 (1.15--1.34)   \< 0.01    1.32 (1.22--1.42)   \< 0.01
  No. of comorbidity                                                      
   1                   1.56 (1.39--1.75)   0.84       1.46 (1.31, 1.64)   0.96
   ≥ 2                 2.47 (2.24--2.73)   \< 0.01    2.13 (1.92--2.36)   \< 0.01

OR, odds ratio; CI, confidence interval.

Adjusted by type of institution, department, and medication.

[^1]: These authors contributed equally to this work.
